ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1041

CKD Awareness and Risk Factor Control in US Adults: Findings from NHANES, 2009-2020

Session Information

  • Top Trainee Posters - 1
    November 06, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 01:12 PM - 01:18 PM

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Chow, Timothy Michael, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Ishigami, Junichi, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States
Background

Chronic kidney disease (CKD) is a major global health concern. Contemporary management focuses on risk factor control to limit progression to kidney failure. Yet, nearly 90% of individuals with CKD in the US are unaware of their diagnosis—missing opportunities for intervention. This study examines risk factor control and clinical management in individuals with CKD, comparing those aware vs. unaware using National Health and Nutrition Examination Survey (NHANES) data.

Methods

Baseline characteristics were compared by CKD awareness. The proportion aware was evaluated overall, across CKD stages, and across NHANES cycles. Univariate and multivariable logistic regression analyses estimated the odds of achieving each risk factor control or medication use, comparing those aware vs. unaware.

Results

In pooled NHANES samples, only 10.1% were aware of CKD. Awareness increased with worsening eGFR and albuminuria. Among those with CKD G4/G5, only 51% were aware.

In crude models, factors positively associated with CKD awareness included statin use (OR = 2.07, 95% CI 1.68–2.56), RASi use (OR = 1.94, 95% CI 1.51–2.48), and LDL-C control <160 mg/dL (OR = 1.95, 95% CI 1.06–3.59). When modeling interactions with hypertension, diabetes, and CHD, CKD awareness was significantly associated with RAAS inhibitor use (OR = 3.63, 95% CI 1.23–10.70) and HbA1c control <8.0% (OR = 5.93, 95% CI 1.11–31.72).

Conclusion

Despite increased awareness with increased CKD severity, awareness of CKD remains remarkably low. Those aware of CKD are likely to be aware of other conditions. Risk factor control were similar in those aware and not aware of their CKD with the exception of use of RAAS blockade which was more likely in those aware of CKD.

Digital Object Identifier (DOI)